ADMA Biologics (NASDAQ:ADMA) Trading Down 5.7% - Time to Sell?

ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report) traded down 5.7% during mid-day trading on Friday . The company traded as low as $16.70 and last traded at $16.59. 1,362,504 shares were traded during mid-day trading, a decline of 63% from the average session volume of 3,647,155 shares. The stock had previously closed at $17.59.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Raymond James Financial upped their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th.

ADMA Biologics Price Performance

The company has a quick ratio of 3.36, a current ratio of 6.58 and a debt-to-equity ratio of 0.22. The firm has a market cap of $3.99 billion, a P/E ratio of 19.68 and a beta of 0.43. The business's 50 day moving average is $19.22 and its two-hundred day moving average is $18.76.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The business had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The firm's quarterly revenue was up 40.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.08 earnings per share. As a group, analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insider Activity

In other ADMA Biologics news, Director Steve Elms sold 194,749 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the transaction, the director owned 87,330 shares of the company's stock, valued at $1,767,559.20. The trade was a 69.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jerrold B. Grossman sold 10,000 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the sale, the director directly owned 478,194 shares of the company's stock, valued at $10,190,314.14. This trade represents a 2.05% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 464,621 shares of company stock valued at $9,644,269 over the last quarter. Company insiders own 3.50% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ADMA. Mark Sheptoff Financial Planning LLC purchased a new position in ADMA Biologics in the fourth quarter worth about $35,000. Skandinaviska Enskilda Banken AB publ purchased a new position in ADMA Biologics in the first quarter worth about $35,000. SVB Wealth LLC purchased a new position in ADMA Biologics in the first quarter worth about $35,000. Toth Financial Advisory Corp raised its holdings in ADMA Biologics by 1,081.6% in the second quarter. Toth Financial Advisory Corp now owns 2,505 shares of the biotechnology company's stock worth $46,000 after buying an additional 2,293 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its holdings in ADMA Biologics by 161.4% in the first quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company's stock worth $49,000 after buying an additional 1,493 shares during the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.